202 related articles for article (PubMed ID: 35842306)
21. Myositis-specific antibodies and clinical characteristics in patients with autoimmune inflammatory myopathies: reported by the Argentine Registry of Inflammatory Myopathies of the Argentine Society of Rheumatology.
Gómez GN; Pérez N; Braillard Poccard A; Gómez RA; Costi AC; García MA; Viola M; Benitez A; Aciar MM; Crespo Espíndola M; Yucra D; Cosatti MA; Pisoni C; Capelusnik D; Lojo MN; Barrios BI; Rivero M; Kisluk B; Granel A
Clin Rheumatol; 2021 Nov; 40(11):4473-4483. PubMed ID: 34159491
[TBL] [Abstract][Full Text] [Related]
22. Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis.
Gupta L; Naveen R; Gaur P; Agarwal V; Aggarwal R
Semin Arthritis Rheum; 2021 Feb; 51(1):113-120. PubMed ID: 33360322
[TBL] [Abstract][Full Text] [Related]
23. The association between myositis-specific autoantibodies and muscle pathologies in idiopathic inflammatory myopathies.
Xu Q; Li QX; Bi FF; Duan HQ; Luo YB; Yang H
Clin Rheumatol; 2021 Feb; 40(2):613-624. PubMed ID: 32671659
[TBL] [Abstract][Full Text] [Related]
24. Severe onset of inflammatory myositis in a child: think to paraneoplastic myositis.
Benvenuto S; Gortani G; Bussani R; Poropat F; Murru FM; Carrozzi M; Tommasini A; Taddio A
Ital J Pediatr; 2021 Jul; 47(1):146. PubMed ID: 34210321
[TBL] [Abstract][Full Text] [Related]
25. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
Muro Y; Ishikawa A; Sugiura K; Akiyama M
Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
[TBL] [Abstract][Full Text] [Related]
26. Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation.
Aggarwal R; Oddis CV; Goudeau D; Fertig N; Metes I; Stephens C; Qi Z; Koontz D; Levesque MC
Rheumatology (Oxford); 2014 Mar; 53(3):433-7. PubMed ID: 24255164
[TBL] [Abstract][Full Text] [Related]
27. Narrative review of autoantibodies in idiopathic inflammatory myopathies.
Liu Y; Zheng Y; Hao H; Yuan Y
Ann Transl Med; 2023 Apr; 11(7):291. PubMed ID: 37090051
[TBL] [Abstract][Full Text] [Related]
28. The Role of Myositis-Specific Autoantibodies and the Management of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: A Systematic Review.
Teel A; Lu J; Park J; Singh N; Basharat P
Semin Arthritis Rheum; 2022 Dec; 57():152088. PubMed ID: 36116345
[TBL] [Abstract][Full Text] [Related]
29. Myositis Specific Autoantibodies: A Clinical Perspective.
Alenzi FM
Open Access Rheumatol; 2020; 12():9-14. PubMed ID: 32021502
[TBL] [Abstract][Full Text] [Related]
30. Analysis of myositis autoantibodies in Chinese patients with cancer-associated myositis.
Li L; Liu C; Wang Q; Wu C; Zhang Y; Cheng L; Wen X; Zeng X; Zhang F; Li Y
J Clin Lab Anal; 2020 Aug; 34(8):e23307. PubMed ID: 32222002
[TBL] [Abstract][Full Text] [Related]
31. [Correlation study on anti-Ro52 antibodies frequently co-occur with other myositis-specific and myositis-associated autoantibodies].
Zheng YM; Hao HJ; Liu YL; Guo J; Zhao YW; Zhang W; Yuan Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 52(6):1088-1092. PubMed ID: 33331318
[TBL] [Abstract][Full Text] [Related]
32. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab.
Aggarwal R; Oddis CV; Goudeau D; Koontz D; Qi Z; Reed AM; Ascherman DP; Levesque MC
Rheumatology (Oxford); 2016 Jun; 55(6):991-9. PubMed ID: 26888854
[TBL] [Abstract][Full Text] [Related]
33. A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.
Satoh M; Tanaka S; Ceribelli A; Calise SJ; Chan EK
Clin Rev Allergy Immunol; 2017 Feb; 52(1):1-19. PubMed ID: 26424665
[TBL] [Abstract][Full Text] [Related]
34. Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study.
Dani L; Holmqvist M; Martínez MA; Trallero-Araguas E; Dastmalchi M; Svensson J; Labrador-Horrillo M; Selva-O'Callaghan A; Lundberg IE
Clin Exp Rheumatol; 2020; 38(1):67-73. PubMed ID: 31365334
[TBL] [Abstract][Full Text] [Related]
35. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis.
Hoshino K; Muro Y; Sugiura K; Tomita Y; Nakashima R; Mimori T
Rheumatology (Oxford); 2010 Sep; 49(9):1726-33. PubMed ID: 20501546
[TBL] [Abstract][Full Text] [Related]
36. [Pathological features of myositis with myositis -specific autoantibodies].
Shimizu J; Mimori T
Rinsho Shinkeigaku; 2014; 54(12):1113-4. PubMed ID: 25672723
[TBL] [Abstract][Full Text] [Related]
37. Characteristics of idiopathic inflammatory myopathies with novel myositis-specific autoantibodies.
Rams A; Kosałka-Węgiel J; Kuszmiersz P; Matyja-Bednarczyk A; Polański S; Zaręba L; Bazan-Socha S
Adv Clin Exp Med; 2021 Dec; 30(12):1239-1248. PubMed ID: 34610217
[TBL] [Abstract][Full Text] [Related]
38. Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies.
Ueki M; Kobayashi I; Takezaki S; Tozawa Y; Okura Y; Yamada M; Kuwana M; Ariga T
Mod Rheumatol; 2019 Mar; 29(2):351-356. PubMed ID: 29532710
[TBL] [Abstract][Full Text] [Related]
39. [Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis].
Gan YZ; Li YH; Zhang LH; Ma L; He WW; Jin YB; An Y; Li ZG; Ye H
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 52(6):1001-1008. PubMed ID: 33331305
[TBL] [Abstract][Full Text] [Related]
40. Idiopathic inflammatory myopathies: CT characteristics of interstitial lung disease and their association(s) with myositis-specific autoantibodies.
Laporte A; Mariampillai K; Allenbach Y; Pasi N; Donciu V; Toledano D; Granger B; Benveniste O; Grenier PA; Boussouar S
Eur Radiol; 2022 May; 32(5):3480-3489. PubMed ID: 35022809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
